Stopping oxytocin mid-labor shortens the process and reduces C-sections
Despite its widespread use throughout the labor process, no advantage exists to continuing oxytocin infusion after the onset of active labor, according to a small trial of 104 women in Israel. Researchers found that stopping oxytocin at 5 cm dilation, instead of continuing it until delivery, shortened labor, though not significantly so, and halved the number of cesarean sections required.
The researchers admit that the study was underpowered and that the findings could be the result of chance, but their results also support the hypothesis that continuing oxytocin once the active phase of labor has begun actually complicates labor by desensitizing uterine receptors to exogenous and endogenous oxytocin.
Daniel-Spiegel E, Weiner Z, Ben-Shlomo I, et al. For how long should oxytocin be continued during induction of labour? BJOG. 2004;111:331-334.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
